Lindsey George: Understanding the Enhanced Activity of FVIII Aurora
Lindsey George, Assistant Professor of Pediatrics at University of Pennsylvania, Director of Clinical In Vivo Gene Therapy at Children’s Hospital of Philadelphia, shared on LinkedIn about a recent article she and her colleagues co-authored, published in Blood, adding:
”Congratulations Johnathan Morris!
This manuscript describes the underlying mechanism of FVIII Aurora (FVIII-R571S), which has 10–20-fold higher affinity for FIXa over FVIII-WT and FIXa-dependent reduced inactivation by A2-domain dissociation and APC cleavage.”
Title: Factor VIII Aurora: A Naturally Occurring Gain of Function FVIII Variant with Enhanced FIXa Affinity
Authors: Johnathan J. Morris, Robert J Davidson, Connor T. Watson, Lindsey A. George
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 3, 2026, 04:09Pedro Perez: Are We Entering a New Era in the Treatment of Intermediate-High-Risk PE?
-
Sep 3, 2026, 04:01Marianne Yee: Supporting Families and Transformative Therapies in Sickle Cell Disease
-
Sep 3, 2026, 03:51Strengthening Bleeding Disorders Care in New Zealand – WFH
-
Sep 3, 2026, 03:42Nathan Connell: FDA Approves Rusfertide for Polycythemia Vera
-
Sep 3, 2026, 03:28Katrina Snow: Learning More About Sickle Cell Disease This September
-
Sep 3, 2026, 01:19Himanshu Aggarwal: 1 mg/kg/d Thalidomide Non-Inferior to Standard Dose in Transfusion-Dependent Thalassemia
-
Sep 3, 2026, 01:03SHOT Urges Safe Component Matching While NHSBT Appeals for Black Donors
-
Sep 3, 2026, 00:52David Wallace: FDA Approves MIMRYLO to Target Iron Regulation and Reduce Phlebotomy Burden
-
Sep 3, 2026, 00:44Same goal, Different molecular strategy – Which FVIIIa Mimetic Gets There How? – RPTH Journal